GSK, Pfizer merger won’t cause Nurofen maker any pain, ACCC says
Competition & Consumer Protection 2019-05-09 8:24 pm By Amelia Birnie | Sydney
Please login to bookmark Close

The Australian Competition and Consumer Commission has signed off on pharmaceutical giant GlaxoSmithKline’s proposed acquisition of fellow heavyweight Pfizer, a merger which will put pain medications Panadol, Voltaren and Advil all under one roof, with the competition cop saying Nurofen maker Reckitt will still be able to compete.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au